Document is current

Article History

Received: 27 October 2023

Accepted: 18 October 2024

First Online: 8 November 2024

Declarations

:

: The study protocol was approved by the applicable Clinical Research Ethics Committees of the participating Spanish clinical sites (Supplementary Table 6). Study procedures were conducted in accordance with the Declaration of Helsinki, as revised in 2013, and good clinical practice guidelines. Informed consent was obtained for the collection of local epidemiological, clinico-pathological, and biological data, and biomarker assessment according to applicable legislation.

: Not applicable.

: J. de la Haba-Rodriguez declares having received research grants from Roche and Pfizer, consulting/advisory fees from AstraZeneca, Amgen, Roche/Genentech, Novartis, Eli Lilly and Pfizer and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer, but declares no non-financial competing interests. A. Prat declares stock and Other Ownership Interests from Reveal Genomics; honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly, Daiichi Sankyo, Amgen, and Guardant Health; consulting/advisory role from Amgen, Roche, Novartis, Pfizer, Bristol-Myers Squibb, Boehringer, PUMA, Oncolytics Biotech., Daiichi Sankyo, Abbvie, AstraZeneca, and NanoString Technologies; research funding from Roche, Novartis, Incyte, and Puma Biotechnology; travel /accommodation expenses from Daiichi Sankyo. Other relationship with companies as, Oncolytics, and Peptomyc S.L.; stock at Reveal Genomics; and patents/royalties from PCT/EP2016/080056, WO/2018/096191, HER2DX filing, and US 63/023785, but declares no non-financial competing interests. A. Guerrero-Zotano declares institutional grant from Pfizer; advisory role honoraria from Novartis, Palex, Pfizer, AstraZeneca and Pierre Fabre; travel grants from Roche, Pfizer, and Novartis, but declares no non-financial competing interests. M. Martin declares having received research grants from Roche, PUMA and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo and Pfizer and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer, but declares no non-financial competing interests. F. Rojo declares research grants from Roche, consulting/advisory fees from BMS, MSD, AstraZeneca, Janssen, Roche/Genentech, Novartis, Eli Lilly, and Daiichi Sankyo, but declares no non-financial competing interests. J.A. Perez-Fidalgo declares research grants from Pharmamar, Novartis and GSK consulting/advisory fees from AstraZeneca, Amgen, Abilify Pharma, GSK Tesaro, Pharmamar and Clovis and speakers’ honoraria from AstraZeneca, GSK Tesaro, Pharmamar, Roche, Clovis, and Pfizer. Co-inventorship of a European patent of response prediction in triple negative breast cancer, but declares no non-financial competing interests. J. Gavila declares having received advisory role honoraria from Novartis Pfizer, AstraZeneca; travel grants from Roche, Pfizer, and Novartis, but declares no non-financial competing interests. All other authors declare no financial or non-financial competing interests.